JP2004508333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508333A5 JP2004508333A5 JP2002524503A JP2002524503A JP2004508333A5 JP 2004508333 A5 JP2004508333 A5 JP 2004508333A5 JP 2002524503 A JP2002524503 A JP 2002524503A JP 2002524503 A JP2002524503 A JP 2002524503A JP 2004508333 A5 JP2004508333 A5 JP 2004508333A5
- Authority
- JP
- Japan
- Prior art keywords
- quetiapine
- pharmaceutically acceptable
- acceptable salt
- treating
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 description 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 4
- 229960004431 quetiapine Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0003126A SE0003126D0 (sv) | 2000-09-05 | 2000-09-05 | Method of treatment |
| PCT/SE2001/001879 WO2002020019A1 (en) | 2000-09-05 | 2001-08-31 | New use of quetiapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508333A JP2004508333A (ja) | 2004-03-18 |
| JP2004508333A5 true JP2004508333A5 (https=) | 2008-09-04 |
Family
ID=20280890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002524503A Abandoned JP2004508333A (ja) | 2000-09-05 | 2001-08-31 | クエチアピンの新規な用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7338948B2 (https=) |
| EP (1) | EP1326616B1 (https=) |
| JP (1) | JP2004508333A (https=) |
| AT (1) | ATE291920T1 (https=) |
| AU (1) | AU2001282832A1 (https=) |
| DE (1) | DE60109799T2 (https=) |
| ES (1) | ES2238469T3 (https=) |
| PT (1) | PT1326616E (https=) |
| SE (1) | SE0003126D0 (https=) |
| WO (1) | WO2002020019A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008526839A (ja) * | 2005-01-07 | 2008-07-24 | アストラゼネカ・アクチエボラーグ | １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| GB0822077D0 (en) * | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
-
2000
- 2000-09-05 SE SE0003126A patent/SE0003126D0/xx unknown
-
2001
- 2001-08-31 ES ES01961576T patent/ES2238469T3/es not_active Expired - Lifetime
- 2001-08-31 AT AT01961576T patent/ATE291920T1/de not_active IP Right Cessation
- 2001-08-31 WO PCT/SE2001/001879 patent/WO2002020019A1/en not_active Ceased
- 2001-08-31 AU AU2001282832A patent/AU2001282832A1/en not_active Abandoned
- 2001-08-31 PT PT01961576T patent/PT1326616E/pt unknown
- 2001-08-31 JP JP2002524503A patent/JP2004508333A/ja not_active Abandoned
- 2001-08-31 DE DE60109799T patent/DE60109799T2/de not_active Expired - Fee Related
- 2001-08-31 US US10/398,307 patent/US7338948B2/en not_active Expired - Fee Related
- 2001-08-31 EP EP01961576A patent/EP1326616B1/en not_active Expired - Lifetime
-
2008
- 2008-01-10 US US11/972,350 patent/US20080108597A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USD492502S1 (en) | Bed | |
| JP2003503454A5 (https=) | ||
| EP1698329A4 (en) | PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES | |
| PL349425A1 (en) | Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament | |
| HUT76788A (en) | N-tert-butyl alfa-(2,4-disulfonyl)-phenyl nitrone, its salts, and their use for the preparation of pharmaceutical compositions | |
| CA2436799A1 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
| CZ20023753A3 (cs) | Substituované thioacetamidy, jejich použití pro výrobu léčiva a farmaceutický prostředek s jejich obsahem | |
| EP1029540A3 (en) | Use of droloxifene for the treatment of cardiovascular diseases | |
| PL355816A1 (en) | Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy | |
| HUP0401201A3 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
| ZA200202521B (en) | 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds. | |
| TWI345975B (en) | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| JP2004506682A5 (https=) | ||
| JP2005508963A5 (https=) | ||
| GB0204331D0 (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| JP2002542248A5 (https=) | ||
| EP1440689A3 (en) | Treatment of neurotic disorders | |
| WO2000008007A3 (de) | Cyclopentabenzofuran-derivate und ihre verwendung | |
| NZ502495A (en) | Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome | |
| JP2004508333A5 (https=) | ||
| JP2002542281A5 (https=) | ||
| DE602005017541D1 (de) | Verfahren zur Herstellung von 1,3,4,5-tetrahydro-2H-3-Benzazepin-2-on-Derivaten und dessen Anwendung in der Herstellung von Ivabradin sowie dessen pharmazeutisch verträglichen Salze | |
| WO2003099265A3 (de) | Pharmazeutische wirkstoffkombination sowie deren verwendung | |
| JP2003522147A5 (https=) |